Biotech Values

[dewophile]

If that’s true then I’m wholly unimpressed by this panel. It’s appropriate to vent that there weren’t more 80+ year olds amd frail patients but it’s not easy for a frail patient to participate in a clinical study. Sometimes you make the best call with the data in hand. If it’s decreasing LRTI in all age groups < 80 and you even see a numeric imbalance in hospitalizations (5 to 1 for GSK, 3 to 1 for PFE) it’s not such a stretch to assume it will have even more impact in even older more frail patients
And all this hullabaloo about GBS every pt recovered and more patients were in the hospital with severe RSV relative to placebo than all GBS combined. The risk benefit to me is quite clear even without perfect data
Anyone who thinks the vaccine is appropriate for 60-64 but not over 65 is a complete idiot and shouldn’t partake in important policy decisions moving forward
(I had given them benefit of the doubt that they were opposed to a shared decision making for this more vulnerable group which then makes them smarter than the “yes” folks IMO)
Anyway this panel can reconvene after some real world data is out and there is still a decent market out there. That’s why this vote didn’t really move the stocks much I guess